SCHEMBL1029926

SCHEMBL1029926

CCCCCc1cccc(C(=O)O)c1C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BID P55957 7/20 0.69
MCL1 Q07820 7/20 0.69
BCL2L1 Q07817 6/20 0.69
BAK1 Q16611 6/20 0.69
KAT8 Q9H7Z6 3/20 0.69
PPARA Q07869 3/20 0.69
PPARG P37231 2/20 0.69
SAE1 Q9UBE0 2/20 0.69
EP300 Q09472 2/20 0.69
KAT5 Q92993 2/20 0.69
KAT2A Q92830 1/20 0.69
KAT2B Q92831 1/20 0.69
F7 P08709 3/20 0.59
F3 P13726 3/20 0.59
MMP2 P08253 2/20 0.59
KDM4E B2RXH2 1/20 0.59
MAPT P10636 1/20 0.59
ALOX15 P16050 1/20 0.59
ECE1 P42892 1/20 0.59
SGMS1 Q86VZ5 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30069215 1.00 BID (0.69) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL301487 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL23277 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL795643 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL485756 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL3258790 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL3033684 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL10767415 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5519496 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5424052 0.98 BID (0.72) BIDMCL1BCL2L1BAK1KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10814303-B2 Process for producing a calcium phosphate reactant, reactant obtained and use thereof in the purification of liquid effluents SOLVAY SA (BE) 2020-10-27 US claimed
EP-4543455-A2 METHODS OF TREATING NEUROLOGICAL VENTILATORY INSUFFICIENCY Enalare Therapeutics Inc. (US) 2025-04-30 EP disclosed
WO-2025080559-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ENALARE THERAPEUTICS INC. (US) 2025-04-17 WO disclosed
US-20250114370-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ENALARE THERAPEUTICS INC (US) 2025-04-10 US disclosed
EP-4504206-A2 RESPIRATORY STIMULANT NASAL FORMULATIONS Enalare Therapeutics Inc. (US) 2025-02-12 EP disclosed
US-20250032496-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT ENALARE THERAPEUTICS INC (US) 2025-01-30 US disclosed
US-20250031718-A1 NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) COMPOSITIONS, METHODS OF MANUFACTURING THEREOF, AND METHODS OF USE THEREOF SOVIDA SOLUTIONS LTD (GB) 2025-01-30 US disclosed
US-20250010049-A1 ORAL DELIVERY OF ACTIVE DRUG SUBSTANCES Biograil ApS (DK) 2025-01-09 US disclosed
US-12150461-B2 Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof Sovida Solutions Ltd. (GB) 2024-11-26 US disclosed
US-12138267-B2 Methods of treating respiratory depression modulated by a non-opioid agent ENALARE THERAPEUTICS INC. (US) 2024-11-12 US disclosed
EP-0442078-A1 Method and agent for the purification of gases and exhaust gases ARASIN GMBH (DE) 1991-08-21 EP disclosed
US-5024929-A Method of preparing coupler dispersions for photographic use EASTMAN KODAK COMPANY (US) 1991-06-18 US disclosed
US-4946768-A NON-DIFFUSING; ABSORPTION OF SPECIFIC WAVELENGTHS MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1990-08-07 US disclosed
EP-0127819-B1 ULTRAVIOLET ABSORBER AND PHOTOGRAPHIC MATERIAL INCLUDING IT MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1988-03-30 EP disclosed
EP-0210409-A2 3-Aminoallylidenemalononitrile uv-absorbing compounds and photographic elements containing them MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1987-02-04 EP disclosed
US-4576908-A 3-DIALLYLAMINOALLYLIDENEMALONITRILE MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1986-03-18 US disclosed
EP-0127819-A2 Ultraviolet absorber and photographic material including it MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1984-12-12 EP disclosed
US-4297438-A USING HYDROPHILIC AND HYDROPHOBIC DEVELOPERS COMPRISING N-SULFOALKYL-N-ALKYL-P-DIAMINOBENZENES AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1981-10-27 US disclosed
EP-0007593-B1 COLOUR-PHOTOGRAPHIC DEVELOPING PROCESS Agfa-Gevaert AG (DE) 1981-01-21 EP disclosed
EP-0007593-A1 Colour-photographic developing process Agfa-Gevaert AG (DE) 1980-02-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250010049-A1 ORAL DELIVERY OF ACTIVE DRUG SUBSTANCES ABCB1, EPCAM, ABCB11 BID 604/4885MCL1 2683/4885BCL2L1 2781/4885
US-12138267-B2 Methods of treating respiratory depression modulated by a non-opioid agent OPRK1, OPRM1, OPRD1 BID 3419/4885MCL1 4481/4885BCL2L1 4029/4885
US-20250032496-A1 METHODS OF TREATING RESPIRATORY DEPRESSION MODULATED BY A NON-OPIOID AGENT OPRK1, OPRM1, OPRD1 BID 3419/4885MCL1 4481/4885BCL2L1 4029/4885
US-20250114370-A1 METHODS AND COMPOSITIONS FOR TREATING DRUG OVERDOSE ADRA2A, ADRA2C, OPRM1 BID 297/4885MCL1 687/4885BCL2L1 1413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.